STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more

The story
GSK has continued its drive to bulk up its pipeline, taking global rights to a multiple myeloma treatment developed in China
How this story developed
Full timelineAlto has tracked this across 3 days of coverage from 1 outlet.
- STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and moreYou are here
Powered by Gab AI
The Story At A Glance
Reading this article now — analysis appears below
💡 AI analysis provides alternative perspectives on current events